Research
Hormonal
Chronic low-grade inflammation (inflammaging) is a key pathophysiologic association in aging, driven by oxidative stress-induced redox imbalance and the accumulation of senescent cells.
Recognize that chronic, low-grade inflammation is a key driver of aging. Strategies to reduce inflammation, such as managing stress, maintaining a healthy weight, and ensuring adequate sleep, may help mitigate age-related degeneration.
GoodSupportsHIGH confidence
Unresolved chronic inflammation during aging may serve as a pathophysiologic association which converts functional changes to the age-related degenerative normal diseases is (Viola and Soehnlein, 2015).
Why this rating
Supported by multiple citations and established theories like the oxidative stress hypothesis.
Source
Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases
Bee Ling Tan et al. · Frontiers in Pharmacology · 2018
DOI 10.3389/fphar.2018.01162
narrative_reviewCited 1,133×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Antioxidants counteract oxidative stress and promote healthy longevity by interrupting free radical propagation and inhibiting their formation, thereby reducing molecular and cellular damage associated with aging.Moderate
- Mitochondria-targeted antioxidants, such as MitoQ, offer greater protection against oxidative damage by crossing the mitochondrial phospholipid bilayer to eliminate ROS directly within the mitochondria.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →